Physician profile
Edward E Janus
NPI 1194749770
$4,215.50
in general payments reported to CMS, 2019-2025
20 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $648 · 2020: $286 · 2021: $1,016 · 2022: $1,391 · 2023: $687 · 2024: $187.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $874.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $874.04 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $950.34 | 2019-2024 | Trelegy Ellipta |
| Abbvie INC. | $858.71 | 2021-2024 | |
| Merck Sharp & Dohme LLC | $452.00 | 2021-2023 | Verquvo, Belsomra |
| Pfizer INC. | $372.87 | 2019-2022 | |
| Janssen Pharmaceuticals, INC | $310.76 | 2019-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $258.01 | 2020-2024 | Jardiance, Synjardy, Tradjenta |
| Novartis Pharmaceuticals Corporation | $254.47 | 2019-2023 | |
| Lilly USA, LLC | $116.23 | 2021-2024 | Mounjaro |
| Novo Nordisk INC | $106.82 | 2019 | |
| Exact Sciences Corporation | $88.12 | 2024 | Cologuard Collection Kit |
| Astellas Pharma US INC | $77.49 | 2019-2020 | |
| Almatica Pharma LLC | $70.25 | 2021-2022 | |
| Hikma Pharmaceuticals USA | $69.01 | 2021-2022 | |
| Boston Scientific Corporation | $46.22 | 2021-2022 | |
| Allergan, INC. | $44.61 | 2019-2020 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Supernus Pharmaceuticals, INC. | $43.23 | 2019 | |
| Biohaven Pharmaceutical Holding Company Ltd. | $37.36 | 2022 | |
| Eyevance Pharmaceuticals LLC | $27.67 | 2021 | |
| Amgen INC. | $16.07 | 2020 | |
| Idorsia Pharmaceuticals US INC | $15.26 | 2023 | Quviviq |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Edward Janus listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.